• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

PathologyWatch Lands $25M for Digital Dermpath Lab Platform

Share:

November 22, 2021

What You Should Know:

Digital lab and pathology platform PathologyWatch, today announced $25 million in Series B funding with participation from Ceros Capital Markets, Rock Creek Capital, Springtide Capital, Spark Growth Ventures, Blueprint Health, Blackbrook Management Group, and existing investors.

– AI in diagnostic services grew by 80% in 2020, largely in response to the COVID-19 pandemic, which also brought to our attention the need for more equitable and accessible healthcare. With this funding, PathologyWatch will continue to be a key contributor in both areas.

The funding will help the company digitize biopsies, increase and equalize access to top skin care physicians, and further AI research as they expand operations across the country.

Full-Service Dermpath Lab

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

PathologyWatch provides fully interfaced EMR reporting and 24/7 access to digital slides for dermatology clinics. For their clients, this means more efficient workflows and direct access to leading dermatopathologists across the country, with broad insurance coverage. PathologyWatch has successfully integrated laboratory information systems, scanners, digital viewer technology, and EMRs into an end-to-end solution for dermatologists.

“We are honored that of all the digital dermpath labs available, dermatologists are increasingly choosing to partner with us,” said Dan Lambert, PathologyWatch CEO and cofounder. “As digital dermatopathology continues to grow, it has the potential to reduce the costs of pathology by billions while creating better patient care for everyone across the country. We’re thrilled to be winning so much volume so quickly.”

Expansion Plans

With the new funding, PathologyWatch will broaden its outreach to dermatologists and conduct further research into skincare diagnostics and AI — allowing patients to receive faster diagnoses and more equitable access to dermatopathology services while enabling labs to work more efficiently and cost-effectively. Additionally, the funding will support operations as the business expands across the country, adding new labs in Texas, Florida, and Arizona.

Source: Hitconsultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Ginger Acquires Technology Assets of Mental Health App LiveBetterGinger Acquires Technology Assets of Mental Health App LiveBetter
  • Owlet Launches New Sleep Wearable for Kids up to 5 Years OldOwlet Launches New Sleep Wearable for Kids up to 5 Years Old
  • Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna TherapeuticsBristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
  • WebMD M&A Deepens Its Informational Resources About ADHDWebMD M&A Deepens Its Informational Resources About ADHD
  • Vuno Signs License Agreement with M3 for Expansion in Japanese MarketVuno Signs License Agreement with M3 for Expansion in Japanese Market
  • Supriya Lifescience Stock Analysis and OutlookSupriya Lifescience Stock Analysis and Outlook
  • Ada Health’s Chief Medical Officer on AI and Building Trust in Digital Health ToolsAda Health’s Chief Medical Officer on AI and Building Trust in Digital Health Tools
  • Altamont Capital Partners Acquires Publicis Healthcare SolutionsAltamont Capital Partners Acquires Publicis Healthcare Solutions

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications